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Abstract
Two human retroviruses, identified as the human T-cell leukemia virus type 1
(HTLV-1) and human immunodeficiency virus type 1 (HIV-1), have been shown to
affect millions of people worldwide. In the context of coinfection, the impact of their
interactions with respect to HTLV-1-induced adult T-cell leukemia and neurologic
disease as well as HIV-1 disease progression has been an understudied area of in‐
vestigation. HTLV-1/HIV-1 coinfections occur frequently, particularly in large met‐
ropolitan areas of the Americas, Africa, Europe, and Japan. The retroviruses
HTLV-1 and HIV-1 share some similarities with regard to their genetic structure,
general mechanisms of replication, modes of transmission, and cellular tropism;
however, there are also significant differences in the details of these properties as
well, and they also differ significantly with respect to the etiology of their pathogen‐
ic and disease outcomes. Both viruses impair the host immune system with HIV-1
demonstrated to cause the hallmark lethal disease known as the acquired immune
deficiency syndrome (AIDS), while HTLV-1 infection has been shown to cause sev‐
eral different forms of T-cell leukemia. In addition, both viruses have also been
shown to cause a spectrum of neurologic disorders with HIV-1 shown to cause an
array of neurologic syndromes referred to as HIV-1-associated neurologic disorders
or HAND, while HTLV-1 has been shown to be the etiologic agent of HTLV-1-asso‐
ciated myelopathy/tropical spastic paraparesis or HAM/TSP. The natural history of
the coinfection, however, is different from that observed in monoinfections. Several
studies have demonstrated utilizing a number of in vitro models of HTLV-1/HIV-1
coinfection that the two viruses interact in a manner that results in enhanced ex‐
pression of both viral genomes. Nevertheless, there remains unresolved controversy
regarding the overall impact of each virus on progression of disease caused by both
viruses during the course of coinfection. Although combination antiretroviral thera‐
py has been shown to work very effectively with respect to maintaining HIV-1 viral
loads in the undetectable range, these therapeutic strategies exhibit no benefit for
HTLV-1-infected individuals, unless administered immediately after exposure. Fur‐
thermore, the treatment options for HTLV-1/HIV-1-coinfected patients are very lim‐
ited. In recent years, allogeneic stem cell transplantation (alloSCT) has been used for
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the treatment of leukemia. In this regard, the case of a leukemic patient positive for
HIV-1 who was cured of their HIV-1 infection while treated with alloSCT for acute
myeloid leukemia has also been examined with regard to impact on HIV-1 disease.
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1. Introduction
HTLV-1/HIV-1 coinfection is very common among drug users, particularly in metropolitan
areas [1, 2]. It is estimated that in endemic areas, 10% of HIV-1-infected patients are coinfected
with HTLV-1 [3]. The frequency of HTLV-1 and HIV-1 coinfections is on the rise, especially in
Africa and South America [4]. Both HTLV-1 and HIV-1 are retroviruses capable of integrating
their proviral DNA genome into the host cell chromosome, thereby establishing a latent
infection, both of which share quiescent CD4+ T cells as their primary target. However, the life
cycle, pathogenesis, and clinical syndromes of these two viruses after infection are very
different within this cellular compartment [5, 6]. In the absence of therapeutic intervention,
there is a striking difference in the prevalence of disease caused by the two viruses with overt
clinical disease far less common after HTLV-1 infection, perhaps because HTLV-1 has existed
within the human population for far longer than HIV-1 and therefore may be more highly
adapted to its human host. This could explain why HTLV-1 has been shown to cause T-cell
transformation and clonal expansion of immortalized cells, whereas HIV-1 induces CD4+ T-
cell death [7]. Since the first cases of HIV-1 were reported early in the 1980s, there has been
much progress with respect to investigating the viral replication cycle, mechanisms of
pathogenesis, as well as the diagnosis and treatment of HIV-1 infection. There are now more
than 30 antiretroviral drugs available for the management of HIV-1 infection, with them, their
modes of inhibition and novel drug discovery techniques have been reviewed previously [8].
A number of drug combinations have been shown to be quite effective with regard to reducing
HIV-1 titers to undetectable levels with subsequent maintenance of this well-controlled state
for many years if not decades, yet they do not cure individuals because the drugs are effective
against actively replicating virus and not the latent, integrated provirus. In the absence of
treatment and subsequent to the development of drug resistance, particularly in the precom‐
bination antiretroviral therapy (cART) era, HIV-1 has been shown to induce severe immuno‐
suppression leading to AIDS with the ultimate development of opportunistic infections and
cancers. In the case of HTLV-1 infection, most patients remain asymptomatic for many years
before the onset of disease. In contrast to HIV-1, only a small percentage of untreated HTLV-1
carriers develop clinically apparent disease [9, 10]. HTLV-1 may cause neurologic problems,
skin and inflammatory disorders, leukemia, and leukemia/lymphoma [9, 10]. The treatments
available for HTLV-1-related complications are limited, and the antiretrovirals used to treat
HIV-1 infection are not efficacious unless taken early after first contact with the virus [6] when
viral replication is responsible for expansion in the number of infected cells as compared to
expansion of infected cells by cell division with the associated integrated HTLV-1 provirus
expanding within the transformed cell population in the absence of infectious HTLV-1
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production [5]. The clinical implications and the molecular interactions between HTLV-1 and
HIV-1 remain understudied. The management of patients coinfected with HTLV-1/HIV-1 is
clearly a challenge. Although it is well known that both HTLV-1 and HIV-1 may cause
progressive diseases within the central nervous system, the focus here will center on the
interaction of these two retroviruses within the immune system and more specifically examine
the impact of HIV-1 infection on the leukemogenic process induced by HTLV-1 in coinfected
individuals as well as the impact of HTLV-1 infection on HIV-1 disease. A summary of the
epidemiology of the two viruses within the human population is shown in Table 1.
HIV-1 HTLV-1
Prevalence 35 million people 20 million people
Transmission ⋅ Sexual transmission
⋅ Parenteral transmission (blood
transfusions, organ transplantation, and via
infected sharp objects)
⋅ Mother to child (breast-feeding and during
delivery)
⋅ Sexual transmission
⋅ Parenteral transmission (blood transfusions,
organ transplantation, and via infected sharp
objects)
⋅ Mother to child (breast-feeding and during
delivery)
Endemic areas Africa, Eastern Europe, South Asia, and
China
Caribbean region, Central Africa, and South
Japan
Table 1. Epidemiological comparison of HTLV-1 and HIV-1 infection and disease
2. Introduction to Human T-cell Leukemia Virus type 1 (HTLV-1)
HTLV-1 is a single-stranded positive-sense RNA, a type C retrovirus, and the etiologic agent
of adult T-cell leukemia (ATL) or adult T-cell leukemia/lymphoma (ATLL) and a progressive
neuroinflammatory disease known as HTLV-1-associated myelopathy/tropical spastic
paraparesis (HAM/TSP), with some similarities to multiple sclerosis due to the progressive
destruction/loss of myelination [11] (also reviewed in [68]). It was the first human retrovirus
discovered [10, 12] and isolated in the United States in the late 1970s, with parallel discoveries
by investigators in Japan [13–15]. In this regard, in the United States, HTLV-1 particles were
detected in fresh peripheral blood lymphocytes and in the T-cell lymphoblastoid cell lines,
HUT 102 and CTLC-3, derived from a 28-year-old African American man suffering from
cutaneous T-cell lymphoma [13]. At nearly the same time, the Japanese investigators isolated
HTLV-1 from a series of cell lines derived from cases of adult T-cell leukemia [13, 15]. Over
the years, HTLV-1 has been shown to be associated with the human population for a much
longer period of time than the HIV-1 with HTLV-1 being detected in remains of a 1,500 Chilean
mummy [16], while HIV-1 sequences have been detected in humans only as far back as the
1920s, many decades before its discovery in the mid-1980s. Based on extensive studies
performed over the past three to four decades concerning clinical parameters, epidemiology,
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molecular biology and virology, immunology, cancer biology, neurobiology, and immune-
and neuropathogenesis of HTLV-1 infection, the virus appears to be much more adapted to
the human population with greater than 95% of the infected individuals harboring the virus
asymptomatically with only small percentages of individuals presenting with symptomatic
disease in the form of leukemia or neurologic disease [9, 17]. This epidemiologic pattern is
quite different than the widespread highly lethal disease of the immune and nervous systems
caused by the HIV-1 in the absence of highly active antiretroviral therapy (HAART) [18] (also
reviewed in [19]).
2.1. HTLV-1 genetic architecture and viral replication
The HTLV-1 genome comprises four main genetic components that include gag, pol, env, and
pX sequences (Figure 1). The gag, pol, and env genes encode the structural proteins and
enzymatic proteins, with a 5 and 3 long terminal repeat (LTR) at each end of the genome, typical
of all viruses in the Retroviridae family. Gag proteins have been designated the group-specific
antigens, which encode the inner virion structural components such as matrix, capsid, and
nucleocapsid. The pro and pol genes encode the protease, integrase, and viral RNA-dependent
DNA polymerase or reverse transcriptase, respectively, and the env gene that encodes the viral
surface and transmembrane envelope proteins [63]. What makes HTLV-1 unique compared to
other retroviruses is the pX region. This region encodes multiple accessory and regulatory
proteins that give HTLV-1 its unique phenotype, one of which is the multifunction oncoprotein
Tax. Tax has been shown to alter the course of gene expression at a number of points during
the course of viral infection and in this regard has been shown to regulate viral replication,
modulate cellular gene expression, induce inflammation, and block apoptosis to pinpoint just
a few, with many of its functions being identified by Tax mutagenesis [20]. More importantly,
this protein is known for its ability to transform T lymphocytes into cancerous leukemic cells,
as described in the following sections. HTLV-1 infection of susceptible cells via transmission
involving transfer of virus from an infected cell to an uninfected cell occurs very efficiently as
a result of specific cell–cell interactions and less efficiently from cell-free viral particle-driven
transmission [21–23]. The replication cycle of HTLV-1 begins with the interaction between the
viral Env glycoproteins and the specific cellular receptor proteins. At least three cellular
receptors have been found to facilitate viral attachment and entry into the cell, and these
include the glucose transporter 1 (GLUT1) [24, 25], neuropilin-1 (NRP-1) [26–28], and heparan
sulfate proteoglycans (HSPG) [29–31]. During the membrane fusion process and after entry of
the viral capsid into the cytoplasm, the viral genomic RNA is reverse transcribed into DNA,
by the viral particle-associated reverse transcriptase. During the process of reverse transcrip‐
tion, the newly synthesized proviral DNA is transported to the nuclear membrane. After the
translocation of the proviral DNA into the nucleus, it is subsequently integrated into the host
cell chromosomal material, which is catalyzed by the activity of the viral-encoded, particle-
associated integrase. Following integration, the transcription of viral RNAs and the translation
of viral proteins are carried out by host machinery with the subsequent assembly of viral
particles and release of infectious virions into the extracellular environment.
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Figure 1. HTLV-1 genomic architecture. A schematic representation of the proviral genome organization, open reading
frames, and viral products of HTLV-1. The organization of the ~9-kb genome is depicted along with the genes and
their transcriptional splicing.
2.2. HTLV-1 infectivity, transmission, and pathogenesis
Although the tropism of HTLV-1 may not represent a direct representation of cells that can be
infected in vivo, studies performed in vitro are often performed to get an approximation
regarding the cell types that may be targeted by a virus during the course of in vivo infection.
If proven susceptible and productive for viral replication, these cell types may then be used
for virus propagation or studies concerning viral pathogenesis. In this regard, during in vitro
propagation of HTLV-1, a wide variety of non-T-cell types have been shown to be susceptible
to viral infection, including human primary endothelial cells [32], monocytes [33], microglial
cells [33], B cells [34], mammary epithelial cells [35], and dendritic cells (DCs) [36], although
the relative level of viral production between the different cell types was shown to differ
greatly. In parallel with these observations, HTLV-1 infection in vivo has been shown to occur
primarily in CD4+ T-cell subsets and to a lesser extent in CD8+ T cells in both asymptomatic
and symptomatic HTLV-1-infected patients [37]. Furthermore, Koyanagi and colleagues [37]
demonstrated HTLV-1 tropism for CD8+ T cells, monocytes, and B cells in the majority of the
asymptomatic HTLV-1-positive individuals studied, as well as in patients with HTLV-1-
related ATL or HAM/TSP. Other groups have also confirmed these observations and have
reported that HTLV-1 also infects macrophages [37], DCs [38], synovial fluid cells [39], and
astrocytes [40] among others when the target cells are examined in vivo. Perhaps of great
importance in the pathogenesis of HTLV-1-associated neurologic disease is the penetration of
the virus into the bone marrow compartment with increasing numbers of HTLV-1 DNA+/
RNA-progenitor cells detected in patients suffering from HAM/TSP as compared to patients
with ATL [41], thus further demonstrating another layer of complexity with respect to target
cell identification that likely involves latency, immune invasion, and adaptation to the host.
HTLV-1 has been shown to be transmitted primarily via three routes: (i) mother-to-child
transmission [42], (ii) sexual intercourse [43], and (iii) parenteral transmission. The vertical
HTLV-1-induced leukemia and retroviral disease
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transmission of HTLV-1 from mother to child occurs via the transfer of maternally infected
lymphocytes to the fetus or newborn through the placenta [44], during delivery [45, 46], or by
breastfeeding [47]. Sexual transmission is a common route of HTLV-1 transmission. Sexual
transmission of HTLV-1 occurs more efficiently from male to female than from female to male.
This might be due in part to the higher numbers of HTLV-1-infected lymphocytes found in
semen than in vaginal secretions [48]. The parenteral transmission of HTLV-1 includes blood
or cellular blood products transferred during the transfusion process [49], organ transplanta‐
tion [50], and possibly percutaneous exposure of the virus via sharing of contaminated objects
such as razor blades and needles, particularly among drug users and healthcare workers [48].
Parenteral transmission represents a large proportion of infected individuals. Regardless of
how the virus is acquired, the infected cells produce numerous progeny virion. Particularly in
the case of T lymphocytes, they too are activated and clonally proliferate, further driving the
expansion and number of cells harboring provirus DNA.
2.3. Cancers and other diseases associated with HTLV-1 infection
Currently, there are approximately 20 million individuals living with HTLV-1 worldwide [7].
In highly endemic regions such as the Caribbean Basin, Central Africa, and southern Japan,
more than 1% of the population is infected with HTLV-1 (reviewed in [51] and [52]). Approx‐
imately 95% of the individuals infected with HTLV-1 remain as asymptomatic carriers
throughout their lives [9, 17]. As previously indicated, HTLV-1 is the etiological agent for
causing two distinct disease phenotypes, ATL and HAM/TSP, the first involving a CD4+ T-cell
malignancy and the second involving a progressive neurological disease. Interestingly, the
specific response of the immune system to the virus seems to influence which clinical mani‐
festation presents and likely includes other factors such as route of transmission, host genetics,
and perhaps aspects of viral genetics.
Less than 5% of the HTLV-1-infected individuals develop ATL after a long period of latency,
which in some cases can be greater than 50 years [53]. ATL is more prevalent in men than in
women with a median onset age of 55 years. ATL can present as four overlapping clinical
manifestations that are broken down into smoldering, chronic, acute, and lymphoma [54, 55].
Approximately 5% of the patients with ATL have been shown to develop the smoldering type
of disease presenting with a number of minor symptoms with leukemic cells infiltrating the
skin causing surface lesions leading to a breach in the epithelial layer of the skin [56]. It has
been estimated that 20% of the HTLV-1-positive patients will develop a chronic form of the
disease. These patients experience similar manifestations as individuals with smoldering ATL,
but they also develop abnormalities in their viscera, leading to impairment of spleen, liver,
and lymphatic functions as well as a slight increase in the levels of leukemic cells [54].
In the acute phase of ATL, the disease progresses quickly, and patients exhibit generalized
swelling of the lymph nodes, elevated calcium and lactate dehydrogenase levels, impairment
of liver and spleen function, skin lesions, bone wounds, and release of cytokines by malignant
cells. All of these abnormalities cause patients to experience fever, cough, malaise, dehydra‐
tion, lethargy, shortness of breath, and inflammation of the lymph nodes. About 55% of
patients with ATL experience the acute form of the disease. Furthermore, around 20% of the
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ATL cases are of the lymphoma type, and they experience inflammation of the lymph nodes,
with no evidence of leukemic cells in the periphery, and general suppression of their immune
system function as summarized in Figure 2. The survival rate associated with ATL from the
time of first disease manifestations is approximately 24.3, 10.2, and 6.2 months for the chronic,
lymphoma, and acute types, respectively [55]. The actual process of transforming T lympho‐
cytes and developing ATL is dependent on the HTLV-1 oncoprotein Tax in part as well as a
number of other factors indicated above.
Figure 2. Summary of pathogenic forms of HTLV-1-induced leukemia. A summary of disease outcomes and sympto‐
matology during the course of HTLV-1-induced leukemia.
Like most other RNA viruses, due to the constraints of genome size, as compared to larger
DNA viruses, the proteins they encode usually have multiple functions. The multifunction
oncoprotein Tax is a 353 amino acid phosphoprotein that is a transcriptional activator of the
LTR, and the protein is primarily responsible for transformation of T lymphocytes. It has been
shown that selected domains of Tax are responsible for interacting with the host transcription
factors NF-κB, ATF/CREB, Sp1, Ets-1, and many others in conjunction with their cognate
binding sites. This leads to enhanced chromatin remodeling, transactivation of the LTR,
activation of host genes, and enhanced viral gene expression. More importantly in the process
of cellular transformation is its chronic activation of signaling pathways (JAK/STAT), expres‐
sion of cytokines and their receptors (IL-2, IL-2Rα), and interaction with cellular tumor
suppressors (p53) and cell cycle kinases and regulators (p15, p16, and p21), to name a few, all
HTLV-1-induced leukemia and retroviral disease
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of which increase the probability of uncontrolled cell division and transformation exhaustively
reviewed [10, 57, 58]. As of now, it is not fully understood how and why Tax, which is a strong
inducer of transformation, only induces ATL in 5% of infected individuals. This could be, in
part, the immune system efficiently removing infected cells and/or combating Tax with specific
host restriction factors. Additionally, Tax has been shown to be secreted from infected cells
and have bystander effects, such as pro-inflammatory cytokines and the infiltration of Tax-
specific CD8+ T cells into the CNS, thus playing a part in HAM/TSP [59–64].
HTLV-1 infection also causes HAM/TSP, a neuroinflammatory disorder that mostly affects the
spinal cord and brain due to chronic proinflammatory cytokines, the destruction of myelin,
and the cells that secrete it, oligodendrocytes [64–66]. It was first thought that there might be
a hormonal component regulating HAM/TSP, as it occurs more frequently and progresses
more rapidly in women than in men, particularly if the first signs of disease occur before
menopause [67]. The onset of HAM/TSP usually happens after 20–30 years of latency [4], and
the average age in which patients experience the first signs of disease is about 43 years of age
[68]. The early phase of HAM/TSP is presented with a profound inflammatory response
resulting in lower back pain, weakness in the lower limbs, and impairment of urinary and
sexual functions. Eventually, a chronic degenerative disorder develops characterized by the
progressive loss of myelin in the thoracic and lumbar regions of the spinal cord [67]. Damage
to the central nervous system (CNS) also occurs in patients with HAM/TSP, likely mediated
by particular cells of the immune system such as CD4+ T cells, CD8+ T cells, DCs, and cells of
the monocyte–macrophage lineage. For instance, it has been proposed (28) that at least three
mechanisms participate in the process of myelin degradation that occurs in HAM/TSP: (i)
direct injury caused by CD8+ T cells, (ii) damage mediated by an uncontrolled cytokine storm,
and (iii) an autoimmune response. Previous studies have shown that infiltrating activated Tax-
specific CD8+ cytotoxic T lymphocytes (CTLs) in the peripheral blood and cerebrospinal fluid
(CSF) induced lysis of HTLV-1-infected cells triggering a pro-inflammatory cytokine storm.
There is evidence that HTLV-1 has been found in the CNS. The release of pro-inflammatory
factors such as TNF-α and IFN-γ secreted by activated CD8+ CTLs injures the CNS. Further
damage may occur as a result of the molecular mimicry between the Tax protein and the
neuronal antigen heterogeneous ribonuclear protein-A1 (hnRNP-A1), which may cause an
autoimmune response [69].
Both HTLV-1 and HIV-1 have been shown to penetrate the bone marrow to varying degrees
during the course of monoinfection, and it is assumed to be the case during the course of
coinfection with both viruses but less information is available in this regard. Clearly, the
relative penetration of the two viruses into the bone marrow compartment during the course
of coinfection may have dramatic effects on HTLV-1- and HIV-1-induced pathogenesis and
disease caused by either viruses, and these pathogenic processes will also be a subject of this
review. These interactions may periodically alter the balance between immune control and
HTLV-1 infection, and the periodic imbalance has also been associated with the etiology of
other inflammatory diseases such as arthropathy, pulmonary alveolitis, uveitis, dermatitis,
Sjögren’s syndrome, Behçet’s disease, thyroid disease, prostatitis, cystitis, hepatitis, polymyo‐
sitis, arthritis, and a sarcoidosis-like disorder [67].
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3. Introduction to HIV-1 infection, pathogenesis, and disease
In 1981, the first cases of AIDS were reported in the United States. At the beginning of the
epidemic,  AIDS  was  first  identified  in  homosexual  men  and  drug  users.  However,  the
epidemic rapidly spread to the general population primarily by heterosexual intercourse
[70]. In 1983, a retrovirus was isolated at the Pasteur Institute in France from a lymph node
biopsy  from  a  homosexual  man  with  lymphadenopathy  presenting  with  AIDS-like
symptoms [71].  Almost  in  parallel  at  the  National  Cancer  Institute  in  Bethesda,  United
States, the same virus was identified from samples of patients suffering from AIDS [72]. In
1986, the virus was named the human immunodeficiency virus (HIV) and demonstrated to
be the causative agent of AIDS [73].
There are two types of HIV, HIV type 1 (HIV-1) and HIV type 2 (HIV-2), which are genetically
and morphologically related viruses that share similarities in their mechanisms of replication
and transmission. However, HIV-1 and HIV-2 differ in clinical disease progression and
geographical distribution. HIV-1 leads to overt disease much faster than HIV-2, with world‐
wide distribution, whereas HIV-2 infections are more prevalent in West Africa [74]. HIV-1 is
divided into four genetically different groups: M (main), O (outlier), N (non-M, non-O), and
P. The group M, which accounts for 98% of the HIV-1 cases worldwide, is further classified
into nine subtypes, with subtype B being the most prevalent within North America [75].
3.1. HIV-1 genetic architecture, entry, and viral replication
HIV-1 is also a type C retrovirus that belongs to the genus lentivirus. On a genomic level, HIV-1
is similar to HTLV-1 in a number of aspects. They both contain 5 and 3 LTR and gag, pol, and
env genes. However, HIV-1 lacks the pX region and encodes for other accessory proteins that
have some overlapping function with those of HTLV-1. HIV-1 proviral DNA encodes for the
accessory proteins Tat, Vpu, Nef, Vif, Rev, and Vpr (Figure 3) [6, 76]. Tat is similar in function
to Tax in the sense it can transactivate the LTR but does not function in cell transformation.
Similarly, both Rev and Rex function to export unspliced and singly spliced RNAs from the
nucleus. While HIV-1 shares sequence similarity at the genome level, it has been shown to
utilize a different receptor for entry.
The HIV-1 envelope glycoprotein gp120 is the trimeric spike on the surface of the virion that
has been shown to mediate attachment to the host target cells by engaging the CD4 receptor
embedded in the plasma membrane. Subsequent structural changes mediate the exposure and
interaction of the V3 region of gp120 to the chemokine coreceptors, either CXCR4 or CCR5
(although others have also been identified to facilitate this process as well), depending on V3
sequence and charge, and mediate fusion of the viral plasma membrane with the host cell
membrane. Once the particle has been internalized, the capsid and associated viral enzymes
and RNA remain associated in the cytoplasm in a capsid-like structure, where the viral reverse
transcriptase continues to be transcribed from viral RNA to DNA (a process that is likely
initiated as the viral particle interfaces with the cell surface proteins involved in viral entry).
As the reverse transcription process continues to completion, the capsid structure transitions
to a preintegration complex (PIC) containing the reverse transcriptase, integrase, capsid, and
HTLV-1-induced leukemia and retroviral disease
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Vpr, and this structure has been shown to be transferred to the nuclear membrane. After entry
into the nucleus, the proviral DNA genome is integrated into the host cell chromosome, with
recent studies characterizing integration site preference and how it changes with disease
progression [77–79]. Once integrated, the proviral DNA becomes part of the cellular chromatin
environment and subjected to host machinery involved in the processes of transcription and
translation. In conjunction with a number of cellular transcription factors and the viral
transactivator proteins Tat and Vpr, transactivation directed by the LTR-driven contained
within the integrated provirus is initiated and used as a template for the transcription of viral
genomic RNAs and viral mRNAs with the subsequent translation of these viral mRNA into
structural, enzymatic, and accessory proteins. From there, the viral polyproteins an proteins
are recruited and aggregate primarily in the vicinity of the plasma membrane, resulting in the
formation and release of mature infectious virions as previously reviewed [80, 81].
3.2. HIV-1 infectivity, transmission, and pathogenesis
As a result of studies performed in cell lines and primary human cells cultured in vitro,
transplanted human cells maintained in vivo in engineered animals, and primary cells
examined in an ex vivo experimental environment, HIV-1 has been shown to most efficiently
infect activated CD4+ T cells [82], although these cells do not need to be activated in order for
infection to occur [83]. Both HIV and HTLV-1 share CD4+ T cells as their cell target, which was
further demonstrated by complementation viral envelopes for each other [84]. In addition to
the CD4+ T-cell compartment, a number of other human cellular compartments are infected
by HIV-1, including cells of the monocyte–macrophage lineage, some subsets of dendritic cells,
microglial cells and astrocytes within the brain, hematopoietic progenitor cells, and endothelial
cells lining the blood-brain barrier [85, 86].
Studies performed in vitro have shown that all HIV-1 isolates infect activated peripheral blood
mononuclear cells (PBMCs). Some isolates are able to infect CD4+ T-cell lines, T-cell leukemia
Figure 3. HIV-1 genomic architecture. A schematic representation of the proviral genome organization open reading
frame and viral products of HIV-1. The organization of the ~10-kb genome is depicted along with the genes and their
transcriptional splicing.
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cell lines, and monocyte-derived macrophages (MDMs). The target cell population and
coreceptor utilization seems to change during disease progression, and the once clear distinc‐
tion between CXCR4-utilizing or X4 versus the CCR5-utilizing or R5 viruses as compared to
the designations referred to as T-tropic and M-tropic now seems to be also guided by the
relative utilization of different levels of the CD4 receptor present on T cells and cells of the
monocyte–macrophage lineage [87]. During the acute phase of infection and to a lesser extent
at later times during the course of disease, primarily due to cART combating replication
competent virus, HIV-1 infects CD4+ T-cell populations, with the resting memory CD4+ T cells
establishing a latent HIV-1 reservoir. The majority of activated and infected CD4+ T cells will
be eliminated, and during this T-cell depletion phase, a portion of the activated CD4+ T cells
will undergo a reprogramming of transcription and translation to allow them to survive and
differentiate into a resting memory cell phenotype. This resting memory CD4+ T-cell can
contribute to the latent reservoir because it was infected and then differentiated into a resting
memory cell or as the cell was differentiated into a memory cell it became infected; regardless
of the mode of infection, the HIV-1 provirus survives, along with a substantial number of
defective proviral genotypes [78, 79]. Because memory CD4+ T cells live for many years, with
a predicted half-life of 44 months [79, 88], these cells maintain one of the critical latent reservoirs
of HIV-1 and a complicating factor in the pursuit to identify an effective means to cure the
HIV-1-infected individual by a new generation of treatment strategies. However, there are
very likely a number of additional cellular reservoirs that facilitate the persistence of HIV-1
during prolonged cART. For example, cells of the monocyte–macrophage lineage in the
peripheral blood and other lymphoid tissues, resident macrophages of the central nervous
system, astrocytes, DCs, follicular dendritic cells (FDCs), hematopoietic progenitor cells
(HPCs) in the bone marrow, and specialized epithelial cells within the kidney likely play a role
in maintaining HIV-1 during clinical latency prior to the start of any form of therapy despite
ongoing immune surveillance and after the start of cART [85]. Each of these cell types present
a unique challenge with respect to a cure based on the IR rate of cell turnover, the relative
proviral genome transcriptional competency, the innate capacity of the virus to move out of
the reservoir, the continued production of infected cells from infected precursors, and the poor
drug penetrating ability into these physiological niches, with resting memory CD4+ T cells and
cells within the brain and bone marrow being prime examples.
It has been suggested that HIV-1 can be transmitted via free virus or HIV-1-infected cells
present in infected blood and body fluids that enter the blood stream of an uninfected
individual. The three routes of HIV-1 transmission are (i) via sexual intercourse, (ii) from
mother to child, and (iii) parenteral transmission [76]. Sexual transmission is the most common
mode of HIV-1 transmission and accounts for the 80% of infections in adults [89] and includes
vaginal, anal, and oral unprotected sex between an infected individual and his or her unin‐
fected partner. The risk of HIV-1 transmission is higher between homosexual men as compared
to the risk during heterosexual intercourse and individuals whom engage in high risk
behaviors [90]; however, this trend can be steadily reduced by prophylactic antiviral use and
educating the public. Parenteral transmission of HIV-1 is usually associated with the transfu‐
sion of contaminated blood, transplant of infected organs, and sharing of infected sharps,
needles, or syringes [76]. Mother-to-child HIV-1 transmission occurs during pregnancy,
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delivery, or breastfeeding. The presence of higher levels of HIV-1 RNA in blood/body fluids
of the infected host has been associated with greater probabilities of transmission [91].
3.3. Diseases caused by HIV-1
According to the World Health Organization (WHO), by the end of 2013, there were 35 million
people living with HIV worldwide, and 1.5 million people died as a consequence of AIDS-
associated diseases [92]. The course of HIV-1 infection consists of three phases of disease:
primary or acute, asymptomatic/chronic, and AIDS. After 2 weeks of initial exposure to HIV-1,
approximately 50–70% of the infected patients experience nonspecific symptoms that do not
last for more than 4 weeks. These symptoms include increase in body temperature, sore throat,
cephalea, joint and muscle pain, general discomfort, and weight loss. Around 70% of patients
will develop a rash on trunk and face [6]. This is followed by a long-term period (in many
individuals, this highly variable period has been thought to be longer than 10 years but may
be altered by many host and comorbidity factors) of asymptomatic chronic infection [93]. This
phase is marked by a loss of CD4+ T cells at an annual rate of 30 to 60 cells/mm3 [6]. HIV-1 titers
in the peripheral blood, and antibodies to HIV-1 become readily detectable [76]. Most patients
do not present major symptoms; however, some experience tiredness and swollen lymph
nodes. Less than 1% of patients in this phase develop AIDS within a period of 1–2 years. The
more advanced disease symptoms begin when the CD4+ T-cell levels drop below 500 cell/
mm3. During this stage, HIV-1-infected patients become immunocompromised, developing
opportunistic infections such as oral candidiasis, pneumococcal infections, tuberculosis, and
infections caused by the herpes simplex and varicella zoster viruses. When the CD4 counts
decrease below 200 cells/mm3, they are clinically diagnosed as having progressed to AIDS.
Here HIV-1-infected patients are at high risk of serious diseases like systemic fungal infections,
toxoplasma encephalitis, and cryptococcal meningitis, reactivation of other latent viruses such
as cytomegalovirus (CMV), and other opportunistic infections, [94], which is primarily due to
the decrease in T-cell count. AIDS patients are also susceptible to developing AIDS- and non-
AIDS-defining cancers. Kaposi sarcoma (KS) induced by human herpes virus 8 and non-
Hodgkin’s lymphoma are two examples of AIDS-defining cancers. Importantly, the incidence
of AIDS-defining cancers and opportunistic infections in HIV-1-infected patients has dropped
since the introduction in 1996 of the highly active antiretroviral therapy (HAART) for the
treatment of HIV-1 in North America, Europe, and Australia [95]. In contrast, the frequency
of non-AIDS-defining cancers such as cervical and anal cancer caused by human papilloma
virus, liver cancer, Hodgkin’s lymphoma, lung cancer, and prostate cancer has increased
among the HIV-1-infected population [95].
4. Impact of HIV-1 on HTLV-1 disease progression
The effect that HIV-1 has on the progression of HTLV-1 infection remains controversial, as
there are very few studies that have directly examined the process interaction. However, it is
likely that the periods of immunosuppression observed during the course of HIV-1 disease
include the first 3–6 months of the primary infection, a time when the CD4+ T-cell compartment
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is acutely targeted by HIV-1, the period involving the transition from asymptomatic clinical
latency to symptomatic disease prior to therapeutic intervention, and last during the final
progressive decrease in the CD4+ T-cell count prior to the availability of therapy or after the
development of drug resistance without the availability of alternative therapies, which may
very likely alter the course of primary HTLV-1 infection, the development and control of ATL,
or the etiology and progression of HAM/TSP. Although HIV-1 has not been shown to infect
bone marrow stem cells, it has been shown to infect more differentiated progenitor cells. In
addition, HTLV-1 has also been shown by Jacobson and coworkers [96] to penetrate the bone
marrow compartment with the detection of HTLV-1 DNA in the absence or presence of
detectable transcription. Given these observations, it is possible that HIV-1 infection of similar
cell populations in the bone marrow may impact HTLV-1 gene expression programming and
alter the functional course of these cell populations with respect to the development and
control of ATL and HAM/TSP.
4.1. Incidence of HAM/TSP among HTLV-1/HIV-1-coinfected patients
Much knowledge of viral coinfection and HAM/TSP has come from longitudinal and cross-
sectional studies of patient cohorts. While much still needs to be understood on a molecular
biologic and immunologic level, these human studies are invaluable with respect to identifying
correlations that allow one to develop experimental designs to explore mechanistic avenues
to determine the role of virus–virus interactions. Based on these studies, it was determined
that less than 2% of the individuals were infected with HTLV-1 develop HAM/TSP [97, 98].
Previous studies have suggested that HIV-1 increases the risk of HAM/TSP in HTLV-1/HIV-1-
coinfected individuals. For example, the incidence of HAM/TSP is 9.7% among HTLV-1/HIV-1-
coinfected individuals in a cohort of patients from New Orleans, Louisiana. These patients did
not present with AIDS, and their CD4+ T-cell levels were normal or slightly elevated [99]. The
occurrence of myelopathy in HTLV-1/HIV-1-coinfected individuals was estimated in a case-
control study in Rio de Janeiro, Brazil. The results indicated that 73% of the coinfected patients
and 16% of the patients infected with only HIV-1 developed myelopathy [100]. Another group
reported that the prevalence of HAM/TSP among HTLV-1/HIV-1-coinfected patients in Brazil
was 8% [101]. Schutte and coworkers [102] observed in a cohort of patients in Pretoria, South
Africa, that HTLV-1/HIV-1-coinfected individuals were prone to developing HAM/TSP at an
earlier age than when infected with HTLV-1. Furthermore, the period of time in which the
coinfected patients remained asymptomatic was shorter than the monoinfected patients (less
than 3 years) [102]. Furthermore, Casseb and colleagues [101] demonstrated that the levels of
HTLV-1 proviral DNA load in coinfected patients with HAM/TSP were five times higher than
in asymptomatic coinfected individuals. HTLV-1 proviral DNA levels in PBMCs varied during
the course of HTLV-1 infection [103]. High proviral DNA levels [104] along with the replication
or migration of HTLV-1-infected lymphocytes to the CNS have been associated with the
development of HAM/TSP [103]. Indeed, Bassi et al. [105] proposed the use of HTLV-1 proviral
DNA loads as a diagnostic tool for the early detection of HAM/TSP. In this regard, other studies
have established the lower limits of detection of HTLV-1 proviral DNA, and these efforts
facilitated studies to distinguish between asymptomatic HTLV-1-infected patients and HAM/
TSP patients. With regard to coinfection, studies have reported that HIV-1 infection increased
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the HTLV-1 proviral DNA levels in HTLV-1-infected patients. Yet, Césaire and colleagues
[106] found no difference between the levels of HTLV-1 proviral DNA in the coinfected patients
compared to those infected with only HTLV-1. Even without understanding the molecular
mechanism of how one retrovirus influences pathology and disease, what is obvious is the
strong association of HAM/TSP and HTLV-1/HIV-1 coinfection (Table 2).
Viral protein Effect on HIV-1 infection Effect on HTLV-1 infection
Tat
Transactivator protein that enhances viral
transcription; can be secreted and cause
apoptosis in uninfected bystander cells
Some studies have suggested that there is minimal effect
by Tat on HTLV-1 infection; other studies have suggested
that HIV-1 Rev is the protein that potentially enhances
gene expression; some studies have shown that HIV-1
does not affect proviral load in PBMCs; there has been a
link between coinfection and increased risk to develop
HAM/TSP and ATL
Tax
Has been shown to be overexpressed in
HTLV-1/HIV-1 coinfection; promotes nuclear
transport of the reverse transcribed HIV-1
DNA; stimulates HIV-1 via activation of NF-
κB (both alone and synergistically with Tat);
has been shown to interact with CCR5, a
major coreceptor of HIV-1, although a role in
disease progression is controversial
Transactivator protein that enhances viral transcription;
largely implicated in the oncogenic potential of HTLV-1;
can be secreted from infected cells resulting in bystander
effects such as upregulation of cytokines and chemokines,
and infiltration of Tax specific CD8+ T cells, which can
influence HAM/TSP
Table 2. Points of intersection between HTLV-1 and HIV-1
The levels of CD4+ T-cell counts and HTLV-1 disease progression in HTLV-1/HIV-1 coinfection
were evaluated in a study conducted in Brazil by Casseb and coworkers. One hundred and
fifty HTLV-1-infected patients were enrolled in the study; 27 of them were coinfected with
HIV-1, and 15 of the coinfected patients had already reported an AIDS-defining event. CD4+
T-cell counts were higher in coinfected individuals with AIDS than in HIV-1-monoinfected
patients (median = 189 cells/mm3 and 89 cells/mm3, respectively; p = 0.036). Moreover, five of
the coinfected subjects who had AIDS and three of the coinfected patients without AIDS
showed signs of HAM/TSP. Three of the eight patients with signs of HAM/TSP also developed
an opportunistic infection. Importantly, the incidence of HAM/TSP in coinfected patients with
AIDS was 20 times higher than those infected with only HTLV-1 infection. These results
supported previous observations that HTLV-1/HIV-1 coinfection was associated with a higher
probability of a more severe HTLV-1 infection along with an increase in the levels of CD4+ T
cells [3]. These results have suggested the possibility that HTLV-1 may inhibit HIV-1 replica‐
tion with a subsequent increase in CD4+ T-cell counts, thereby enhancing HTLV-1 disease
progression. Based on these observations, current research has centered on a more in-depth
molecular analysis with respect to how HTLV-1 and HIV-1 impact each other during the course
of dual infection.
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5. Impact of HTLV-1 on HIV-1 disease progression
The influence of HTLV-1 infection on the development of AIDS in HIV-1-coinfected patients
is not well understood. Several studies have indicated that HTLV-1 infection promotes HIV-1
replication, accelerating the development of AIDS, while other reports have shown that
HTLV-1 actually inhibits HIV-1 infection [4]. The conflicting results reported are likely due in
part to the diverse antiretroviral regimens used to treat HTLV-1/HIV-1-coinfected patients
[104]. In addition, the timing with respect to the introduction of the second virus (HTLV-1 or
HIV-1) may have great impact on HIV-1 replication and disease.
Prior to the HAART era, Bartholomew and colleagues [107] reported the results of a study
conducted in Trinidad with 40 HIV-1-positive homosexual men, 6 of them coinfected with
HTLV-1. The coinfected individuals were severely immunocompromised compared to the
HIV-1-monoinfected patients. Irrespective of sex and CD4+ T-cell counts, a retrospective case-
control study performed in Bahia, Brazil, showed that people living with HTLV-1/HIV-1
coinfection exhibited a shorter lifespan than HIV-1-monoinfected patients. The mean survival
time for controls was 2,430 days, whereas for HTLV-1/HIV-1-coinfected patients, it was 1,849
days, with a p = 0.02 when comparing the two groups [108]. The reduced survival was also
observed in children [109].
Scapellato and colleagues [110] reported that in HTLV-1/HIV-1-coinfected patients naive to
treatment,  CD4+  T-cell  counts  were  higher  in  the  coinfected  patients  than  in  HIV-1-
monoinfected  patients  at  the  time  of  an  AIDS-defining  illness.  A  case-control  study  to
characterize the phenotype of CD4+ T cells during HTLV-1/HIV-1 coinfection was conduct‐
ed with 701 HAART-naïve,  HIV-1-positive African adults.  Within this patient cohort,  29
patients were found to be coinfected with HTLV-1. Each coinfected patient was matched
by  age  and  sex  with  two  HIV-1-monoinfected  individuals.  The  study  also  included
unmatched healthy controls. CD4+ T-cell levels, markers of CD4+ T-cell activation, and HIV
viral load were the parameters used to assess HIV-1 disease progression. The results showed
that coinfected patients exhibited higher levels of CD4+ T cells (median = 525 cells/mm3 and
274 cell/mm3, respectively; p < 0.05) with higher levels of expression of the activation markers
CD25 and CD45RO and lower expression levels of CD45RA and CD62L (markers of naïve
T cells) in coinfected individuals as compared to monoinfected individuals. Furthermore,
coinfected  patients  exhibited  an  increase  in  HIV-1  proviral  DNA  load  as  compared  to
monoinfected  subjects.  Despite  the  normal  or  higher  levels  of  CD4+  T  cells,  coinfected
patients  still  progressed to  AIDS [111].  These  observations  imply that  HTLV-1 infection
enhances HIV-1 progression via loss of naïve CD4+ T cells, with an overall increase in total
CD4+ T cells and an increase in HIV-1 viral load, key features with respect to the develop‐
ment of AIDS. The lymphocytosis observed in coinfected patients might have been caused
by  the  Tax  oncoprotein  encoded  by  HTLV-1.  Tax  inhibits  the  cellular  mechanisms  in‐
volved in DNA repair and induces cell transformation and immortalization [111, 112].
The impact of HTLV-1 on the immune response during coinfection with HIV-1 was evaluated
using quiescent PBMCs from HTLV-1/HIV-1-coinfected patients as well as from HIV-1 and
HTLV-1-monoinfected individuals. The Th1 cytokine pathway appeared to be overstimulated
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during HTLV-1/HIV-1 coinfection, as PBMCs from coinfected patients produced increased
levels of IL-2 and IFN-γ compared to PBMCs from HIV-1 and HTLV-1-monoinfected individ‐
uals. These results implied that overproduction of Th1 cytokines during the course of HTLV-1/
HIV-1 coinfection could be augmenting the overall negative impairment of the immune system
induced by HIV-1 [113], which normally influences a Th2 response during chronic infection.
Curiously, the correction to a Th1 response does not seem to correct for the shortened lifespan
and a possible increase in progression to AIDS. It should be noted that there was obviously
patient-to-patient variability, differences in phenotype depending on viral genotypes, and the
length of time involving mono or dual infection.
6. Molecular interactions between HTLV-1 and HIV-1
To this point, we have discussed the impact that HIV-1 has on HTLV-1 disease progression,
particularly on the occurrence of HAM/TSP, as well as the effect of HTLV-1 on HIV-1 infection.
Clearly, HTLV-1/HIV-1 coinfection alters the course of disease caused by either virus along as
assessed by proviral DNA loads, CD4+ T-cell death and proliferation assessments, and overall
immunologic assessment, pathogenesis, and disease indicates that the presence of both viruses
negatively impacts human health as compared to the presence of either virus alone. Based on
these observations, investigators have also explored the molecular interactions between
HTLV-1 and HIV-1 that could be influencing the development of HTLV-1 disease or HIV/AIDS
during HTLV-1/HIV-1 coinfection. In vitro experiments involving superinfection with the
HIV-1 molecular clone HIV-1IIIB on two HTLV-1-transformed cell lines, MT2 (an HTLV-1-
producer cell line) and 81-66/45 cell line (an HTLV-1 nonproducer cell line), have demonstrated
that HIV-1 infection activates HTLV-1 and increases the levels of HTLV-1 proviral DNA in
both HTLV-1-transformed cell lines [114]. Additional studies performed by Zsabó and
colleagues [115] have shown that in vitro HTLV-1/HIV-1 coinfection of macrophages by both
viruses results in increased replication of both viruses. The presence of the HTLV-1 Tax protein
promoted nuclear transport of the newly reverse transcribed HIV-1 DNA, whereas the
mechanism by which HIV-1 infection enhanced HTLV-1 gene expression did not appear to
involve the HIV-1 Tat protein.
In a tripartite coculture assay using Jurkat T cells transfected with an HTLV-1LTR-driven
reporter construct designated Jurkat/HTLV-1-Luc with a chronically infected HTLV-1 cell line,
HTLV-1-MT2, that has also been infected with HIV-1IIIB via cell-to-cell transfer of virus from
HIV-1IIIB-infected H9 cells, Sun and coworkers demonstrated that HIV-1 infection induced an
80-fold increase in LTR-dependent HTLV-1 gene expression. It was also demonstrated that the
increase in transcriptional activation of HTLV-1 genes occurred in a mechanism that was
dependent on the HTLV-1 Tax protein, the HIV-1 gp120/gp41 complex, and CD40. These
results suggested that HIV-1 infection promoted the development of syncytium among the
cell lines examined in these studies, thereby acting as a channel for HTLV-1 Tax to translocate
from the HTLV-1-infected MT2 cells to the HTLV-1-LTR-Jurkat cells, thereby providing an
explanation as to how coinfection with HIV-1 and HTLV-1 may transactivate the LTR of latent
provirus in neighboring cells [116]. Using an in vitro model of HTLV-1/HIV-1 coinfection, Roy
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and colleagues confirmed that HIV-1 virus alone or the accessory protein Tat can enhance
HTLV-1 gene expression. Culturing the NO-HTLV-1 cell line, an HTLV-1-infected cell line
established by exposure of the cells to an HTLV-1 clinical isolate, in the presence of cell-free
HIV-1 virion alone (HIV-1IIIB), doubled the amount of HTLV-1 gene expression [117–119].
Additionally, the NO-HTLV-1 cells were exposed to recombinant HIV-1 Tat protein alone,
subsequently resulting in an increase in the expression of HTLV-1 matrix protein expression
(p. 19). Furthermore, the majority of HTLV-1-infected cells colocalized with HIV-1 virions,
indicating HLTV-1 gene expression and transactivation, was dependent and correlated with
the presence of HIV-1 virion or Tat [2].
With respect to the interactions between HTLV-1 and HIV-1 that affect HIV-1 expression,
Leung and coworkers [120] first reported that the HTLV-1 Tat protein stimulates HIV-1 via
activation of NF-κB. Later, studies by Böhnlein and colleagues [121] confirmed that in vitro
HTLV-1/HIV-1 coinfection assays indicated that HTLV-1 enhanced HIV-1 expression utilizing
a mechanism dependent on HTLV-1 Tax. These experiments revealed that HTLV-1 Tax protein
stimulates T cells and promotes transcriptional activation of the HIV-1LTR via interaction with
the cellular protein HIVEN86A. Additional studies indicated that HTLV-1 Tax also works
synergistically with HIV-1 Tat to increase HIV-1 via stimulation of NF-κB [122]. Culturing
HTLV-1-producing MT2 cells with HIV-1 isolates from quiescent CD4+ T cells from HIV-1-
infected patients treated with HAART upregulated HIV-1 expression. HTLV-1 Tax or the Env
glycoprotein alone was sufficient to induce HIV-1 replication [123].
7. Treatments for HIV-1 and HTLV-1 infections
The current approach to effectively treat HIV-1-infected patients involves the use of a combi‐
nation of antiretroviral drugs that inhibit a number of steps within the HIV-1 replication cycle,
including the reverse transcription process, integration, and proteolytic processing of struc‐
tural polyproteins, thereby reducing the production of mature infectious HIV-1 virions that
involves the HIV-1-encoded protease [124]. By 2011, the FDA had approved 26 antiretrovirals
for the treatment of HIV-1 [6] with now more than 30 agents approved for use in humans to
treat HIV-1 infection [8]. The rationale of using highly active antiretroviral therapy (HAART)
or also referred as combination antiretroviral therapy (cART) in HIV-1-infected individuals
has been to minimize the development of drug-resistant virus while effectively reducing the
viral load to undetectable levels for prolonged periods of time, in essence, the establishment
of a manageable chronic disease. As mentioned previously, although cART reduced actively
replicating virus, it does not remove active or defective integrated and latent provirus. To
affectively “cure” and HIV-infected individual, every copy of proviral DNA must be removed.
Recently, much attention has been focused on purging and excising the latent reservoir by the
shock and kill method (HDAC inhibitors) and gene-editing enzymes (zinc-finger nucleases,
TALENS and CRISPR/Cas9) [125–128], as previously reviewed [129, 130]. The shock and kill
strategy has involved reactivating latent virus reservoirs from resting memory CD4+ T cells
with this process leading to a contraction in the size of the reservoir post activation in combi‐
nation with cART therapy that leads to the destruction of the activated cell and the prevention
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of infection of uninfected T cells. Additional therapeutic strategies have recently focused on
the use of gene-editing systems involving protein-based enzymes that have been designed to
seek out specific HIV-1 proviral DNA sequences and induce double-stranded DNA breaks
that can induce nucleotide deletions and removal of whole gene segments [126, 130]. Many of
these techniques are in basic discovery phases for the treatment of infected cells with the goal
of eliminating integrated provirus. These technologies hold great promise to eliminate
integrated retroviral genetic information thereby curing the infected cell.
In the case of HTLV-1 infection, reverse transcriptase inhibitors stop HTLV-1 replication in
vivo but can only prevent infection if they are taken immediately after first contact with the
virus [131, 132]. The current therapeutic options for HTLV-1 infection consist of a number of
chemotherapeutic agents for lymphoma and the combination of zidovudine and interferon-α
(IFN-α) for the management of acute, smoldering, and chronic ATL. The clinical management
of ATL continues to be challenging because it has been shown to be a highly lethal type of
cancer resistant to many of the currently available anticancer drugs (Figure 4) [124]. In 1996,
Borg and colleagues [133] successfully treated and caused cancer rejection in an Afro-Carib‐
bean female with ATL using a combination of chemotherapeutic agents (cyclophosphamide,
doxorubicin, and etoposide) and allogeneic bone marrow stem cell transplantation (alloSCT).
In the case of people older than 50 years, alloSCT treatment is given with low doses of
chemotherapeutic drugs. Retrospective studies indicate that 30–40% of ATL patients who have
undergone alloSCT treatment become long-term survivors [134]. The use of the humanized
defucosylated antiCCR4 antibody in patients with ATL has also had promising results [135,
136] with HAM/TSP [137]. Concurrently, the treatment for HAM/TSP and its secondary effects
involves the use of spasmolytic drugs, prednisone, danazol [138], valproic acid [139], prosul‐
tiamine [140], IFN-α [141–143], IFN-β-1a [144–146], or vitamin B1 [147].
The management of HTLV-1/HIV-1 coinfection can be challenging due to the lack of efficacy
of antiretroviral therapy with respect to the inhibition of HTLV-1 replication as well as the
disparate effects one therapy or compound may have on the other virus. One of the drugs
commonly used for HTLV-1 infection is IFN-α. However, the clinical benefits of IFN-α for
HIV-1-infected patients are controversial. In vitro, IFN-α downregulates HIV-1 replication in
macrophages and T cells and halts the formation of mature HTLV-1 virions. Importantly, IFN-
α treatment induces caspase-3-mediated apoptosis of HTLV-1/HIV-1IIIB-coinfected MT-4 cells,
but not HTLV-1-monoinfected MT-4 cells. Interestingly, IFN-α treatment did not affect
HTLV-1 infectivity but markedly reduced HIV-1 replication, with an approximately 1000-fold
decrease in HIV-1 p24 antigen expression [124]. These immediate differential affects on therapy
of these two viruses also project a possible role of coinfection in influencing ATL and
HAM/TSP prominence and therapeutic strategy for treatment.
The incidence of ATL in HTLV-1/HIV-1-coinfected individuals has not been widely reported
yet. Shibata and colleagues reported a case involving a 43-year-old African American male
with ATL that was positive for both HTLV-1 and HIV-1. The patient underwent three phases
of treatment achieving at least 12 months of remission. The first stage consisted of daunoru‐
bicin, prednisone, and vincristine. Then the patient was placed on cis-platinum, etoposide,
cytosine arabidoside, and dexamethasone. During the third phase, the patient was treated with
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zidovudine. PCR analysis of PBMCs detected HTLV-1 in 1/1,000 cells and HIV-1 in a similar
fraction [148].
Furthermore, Hütter and colleagues used alloSCT to treat a 40-year-old white male who
suffered from acute myeloid leukemia and was also HIV-1-positive. The patient received the
transplant from an HLA-matched donor who was homozygous for the CCR5 delta32 deletion.
Importantly, a homozygous 32-bp deletion in the CCR5 allele has been shown to confer long-
term resistance to HIV-1 infection with CCR5-utilizing viruses but not CXCR4-utilizing
viruses. The patient was infected with HIV-1 more than 10 years earlier and had received cART
for the previous 4 years. At the time of his leukemia, he was asymptomatic with respect to HIV
disease. Initially, the patient was treated with chemotherapy, after which time he suffered from
a rebound in his HIV-1 viral load and a relapse in his leukemia. At this time, he received the
alloSCT, which successfully treated the leukemia. In addition, the patient stopped taking the
cART and his HIV-1 viral loads were undetectable. After 20 months of follow-up, this patient
was free of both the HIV-1 infection and the leukemia [149]. While these in vitro and in vivo
studies and clinical trials have revealed a great deal of information about co- and monoinfec‐
tion of HTLV-1/HIV-1-infected individuals, much more research is needed to help manage
these lifelong chronic infections.
Figure 4. Current diagnosis and treatment of HTLV-1-induced ATL. Summary of criteria used to diagnose previously
identifiable forms of ATL and a brief overview of currently available treatments are shown.
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8. Summary and concluding remarks
We have discussed a number of diseases caused by infection with two common human
retroviruses, HTLV-1 and HIV-1, alone or within the context of coinfection. As previously
shown by epidemiological studies, coinfection with these two viral pathogens occurs fre‐
quently among illicit drug users, and its incidence is on the rise particularly in regions around
the world where both viruses are endemic. Although HTLV-1 and HIV-1 are both retroviruses
and as such share a number of genomic structural features, similar events within the replication
cycle, and common modes of transmission, the overall pathogenic outcomes and the associated
diseases they cause are very different except, for the most part, they all occur within the context
of the immune and nervous systems with other end organs also involved. Additional infor‐
mation relevant to epidemiology, virology, immunology, immune- and neuropathogenesis,
diagnosis, molecular mechanisms of disease, treatment, and clinical management are also
discussed within the context of mono- and coinfection with these two important human
retroviruses. Despite large bodies of information available concerning the molecular patho‐
genesis and disease resulting from monoinfections, there is much less information concerning
the molecular interactions between HTLV-1 and HIV-1 replication machinery as well as the
implications each virus has on disease progression resulting from the pathogenic outcomes
when both viruses are replication in the same cells or neighboring cells within the same tissue
compartment. Clearly, studies of HTLV-1/HIV-1 coinfection have been complicated by the fact
that most of these studies have been conducted after the initiation of cART for suppression of
HIV-1 infection (although many of the coinfection studies have been performed in countries
where delivery of optimal cART has been difficult). With regard to the molecular interactions
between the two viruses, even though both viruses target CD4+ T cells, HIV-1 infection usually
results in lytic replication in activated T-cell populations, whereas HTLV-1 infection usually
results in more limited replication and gene expression and ultimately induces clonal expan‐
sion of selected CD4+ T-cell populations. Interestingly, the bone marrow compartment is
penetrated by both HTLV-1 and HIV-1 during the course of disease; the penetration of this
compartment appears to seed each virus into different cellular compartments [41, 85, 150].
With respect to HIV-1, the stem cell population within this compartment appears to be spared
of viral infection with virus only seeded into more committed or differentiated progenitor cell
compartments. The binding of HIV-1 particles to stem cells has been shown to alter their
functional properties despite the absence of detectable levels of viral entry into stem cells.
However, following HTLV-1 infection, there appears to be differential gene expression within
cellular compartments within the bone marrow with much greater numbers of DNA+RNA+
progenitor cells in individuals suffering from HAM/TSP as compared to individuals with ATL
where there are far fewer DNA+RNA+ progenitor cells [61, 64]. The significance of these
molecular interactions within the context of bone marrow cell populations remains unresolved
during the course of monoinfections and remains to be examined in HTLV-1/HIV-1 coinfec‐
tions. The interaction of both viruses with the bone marrow compartment during the course
of mono- and coinfection within the same or different bone marrow-infected cell populations
will likely play an important role in the pathogenesis of diseases caused by both viruses.
Clearly, studies with a greater number of larger coinfection cohorts will be required to
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approach defining molecular mechanisms, diagnosis, treatment, prevention, and overall
clinical management of diseases caused by HTLV-1/HIV-1 coinfection. It would also seem
important to obtain a better understanding concerning the relationship between the timing of
HIV-1 infection relative to the course of HTLV-1-induced disease. Interestingly and perhaps
relevant to thinking about this problem is the epidemiologic data suggesting that individuals
that suffer from ATL as compared to HAM/TSP are more likely to have been infected by
mucosal membrane exposure early in life often as a result of vertical transmission of HTLV-1
as compared to a blood stream exposure of the virus as a result of IV transmission associated
with illicit drug abuse [151]. Clearly, the immunosuppression that occurs as a result of primary
HIV-1 infection and later during the course of disease with individuals that first seek medical
attention for symptoms consistent with HIV-1 disease prior to the start of cART may have great
impact on the initial phases of HTLV-1 disease depending on the size and functionality of the
T-cell compartment during the primary HTLV-1 infection. If these predictable periods of
immunosuppression occur at critical phases of already ongoing HTLV-1-induced disease, the
impact of HIV-1 on the course of HTLV-1 disease could be significant whether the individual
is headed toward neuroinflammatory or leukemic disease. Clearly, these interactions will pose
significant challenges with respect to the clinical management of HTLV-1-induced disease,
while HTLV-1 infection could alter the course of HIV-1 disease depending on what impact the
neuroinflammatory state associated with the development of HAM/TSP may have on HIV-1
infection of the CD4+ T-cell compartment and what impact of polyclonal or monoclonal
expansion of the CD4+ T-cell compartment associated with HTLV-1-induced leukemogenesis
may have on productive HIV-1 infection and replication in these T-cell compartments. Finally,
the discussion of an HIV-1-positive patient suffering from ATL and another case with an
HIV-1-positive patient with acute myeloid leukemia with respect to the impact of bone marrow
stem cell replacement therapy on controlling HTLV-1-induced cancer and impact on ongoing
HIV-1 disease was examined. In both cases, HIV-1 disease was well controlled at the time of
the bone marrow transplant. Interestingly, they both achieved remission of the leukemia, and
the HIV-1 and HTLV-1 titers of the first case were very low after treatment, and in the second
case, the HIV-1 infection has been apparently cured. This is clearly a better understanding of
the molecular interactions between HTLV-1 and HIV-1 and their respective host cell targets
with regard to cellular coinfection or cellular interactions altered by viral coinfection of
different cellular compartments.
The clinical management of HTLV-1 and HIV-1 mono- and HTLV-1/HIV-1 coinfection will be
greatly enhanced by the identification of additional druggable viral or cellular targets to
enhance the effective long-term clinical management of HTLV-1- and HIV-1-induced disease
outcomes stemming from monoinfections (long-term suppression of viral gene expression in
either case with minimal impact of viral infection on host cell function) prior to the encounter
of the second virus. A second therapeutic approach will involve curing HTLV-1- and HIV-1-
infected patients by elimination of susceptible target cell populations by targeted elimination
of cellular receptor epitopes rendering normally susceptible cells refractile to viral infection
while maintaining the normal cellular function of these host cell proteins. In parallel with these
types of experimental studies, additional types of experimentation will involve the eradication
of HTLV-1 and HIV-1 infections by site-specific excision of integrated HTLV-1 and HIV-1
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proviral DNA with minimal off target impact on host cell function. Clearly, this is exciting
technology with great promise to completely eliminate latent or persistent viral infections
without having to activate latent viral gene expression to kill latently infected cells [125–130,
152]. The goal of eliminating both defective and completely functional HIV-1 and HTLV-1 will
likely be very critical since it is entirely possible that nonactivatable defective proviruses may
still be able to drive the expression of viral proteins (gp120, Tat, Vpr, and Nef) that may cause
detrimental effects to neighboring or distant cells in the absence of lytic infectious virus
production. Many challenges await this experimental approach, including the exact nature of
existing viral reservoirs, the genetic variability of the latent virus, and the delivery of excision
technologies to tissue-specific reservoirs, including memory CD4+ T-cell subpopulations,
specific cell populations within the monocyte–macrophage lineage, as well as cell populations
within the brain and other tissues. Perhaps central to basic and translational science is the
development of tomorrow’s translational solutions to today’s challenges leading to effective
solutions to clinical problems.
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